Literature DB >> 11980623

Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men.

C Rolf1, S Kemper, G Lemmnitz, U Eickenberg, E Nieschlag.   

Abstract

OBJECTIVE: In a phase I single-centre, open, randomized study, the pharmacokinetics of two doses of a transdermal testosterone gel containing 2.5% testosterone were evaluated in 26 healthy male volunteers.
DESIGN: To eliminate the influence of endogenous serum testosterone, gonadotrophins and endogenous testosterone secretion were suppressed by a single intramuscular injection of 400 mg norethisterone enanthate. Fourteen men applied 5.0 g and 12 men applied 2.5 g testosterone gel daily for 10 days. Half the men in each group washed the gel off 10 min after it had been applied.
RESULTS: In all the men, a marked suppression of LH, FSH, testosterone, dihydrotestosterone (DHT) and oestradiol was observed after norethisterone treatment. Physiological serum concentrations of testosterone were restored during the 10-day treatment period in the group of men applying 5.0 g testosterone gel. Increasing serum concentrations of testosterone from day 1 to day 10 were observed. Oestradiol and DHT concentrations did not exceed normal values. Washing 10 min after gel application did not influence the resorption of testosterone. A dose of 2.5 g testosterone gel was insufficient to achieve physiological serum concentrations of testosterone.
CONCLUSION: Testosterone replacement treatment with 5.0 g of this 2.5% testosterone gel is able to achieve constant physiological testosterone concentrations in gonadotrophin-suppressed men. Washing the skin after 10 min does not influence the pharmacokinetic profile and thus significantly reduces the risk of contamination of female partners or infants.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980623     DOI: 10.1530/eje.0.1460673

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Endocrine and metabolic alterations in obstructive sleep apnea syndrome.

Authors:  F Lanfranco; L Gianotti; M Maccario
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

Review 2.  Testosterone hormone replacement therapy: state-of-the-art and emerging technologies.

Authors:  Marie-Laure Leichtnam; Hervé Rolland; Patrick Wüthrich; Richard H Guy
Journal:  Pharm Res       Date:  2006-06-09       Impact factor: 4.200

Review 3.  [Hypogonadism in the elderly man. Reliable diagnosis and therapy].

Authors:  M Zitzmann; E Nieschlag
Journal:  Internist (Berl)       Date:  2003-10       Impact factor: 0.743

Review 4.  Testosterone replacement therapy in male hypogonadism.

Authors:  M Byrne; E Nieschlag
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

5.  Dimethandrolone Undecanoate, a Novel, Nonaromatizable Androgen, Increases P1NP in Healthy Men Over 28 Days.

Authors:  Arthi Thirumalai; Fiona Yuen; John K Amory; Andrew N Hoofnagle; Ronald S Swerdloff; Peter Y Liu; Jill E Long; Diana L Blithe; Christina Wang; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.